SCHEMBL14712973

SCHEMBL14712973

CCN1C(=O)/C(=C/C=C/c2ccc(F)cc2)C(=O)NC1=S

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.55
KMT2A Q03164 10/20 0.55
MAPT P10636 10/20 0.55
ALDH1A1 P00352 6/20 0.55
MITF O75030 3/20 0.55
NPSR1 Q6W5P4 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MDM2 Q00987 1/20 0.55
NTSR1 P30989 1/20 0.55
RECQL P46063 5/20 0.49
POLB P06746 4/20 0.49
DNMT1 P26358 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
APEX1 P27695 2/20 0.49
HPGD P15428 2/20 0.49
MCL1 Q07820 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
NSD2 O96028 1/20 0.49
THRB P10828 1/20 0.49
ALOX12 P18054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14713066 0.89 MEN1 (0.64) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14712995 0.88 BCL2A1 (0.61) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14712869 0.88 BCL2A1 (0.61) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14713002 0.86 MEN1 (0.48) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14712957 0.83 MAPT (0.57) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14712882 0.82 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14713020 0.79 MAPT (0.48) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14712962 0.78 KMT2A (0.53) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL14713052 0.78 KMT2A (0.53) MEN1KMT2AMAPTALDH1A1MITF
SCHEMBL16543001 0.77 KMT2A (0.51) MEN1KMT2AMAPTALDH1A1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MEN1 2410/4885KMT2A 2749/4885MAPT 2828/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MEN1 1885/4885KMT2A 3262/4885MAPT 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.